{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T03:29:22Z","timestamp":1768879762071,"version":"3.49.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:00:00Z","timestamp":1764806400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:00:00Z","timestamp":1764806400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"name":"CorEvitas, LLC"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s40744-025-00811-4","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T13:55:35Z","timestamp":1764856535000},"page":"195-212","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness of Tofacitinib in Patients with Psoriatic Arthritis Initiating Monotherapy Versus Combination Therapy: Results from the CorEvitas Psoriatic Arthritis\/Spondyloarthritis Registry"],"prefix":"10.1007","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4639-0775","authenticated-orcid":false,"given":"Alexis","family":"Ogdie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Middaugh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taylor","family":"Blachley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tran","family":"Bourgeois","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"You-Li","family":"Ling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajiv","family":"Mundayat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lara","family":"Fallon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karim R.","family":"Masri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip J.","family":"Mease","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,4]]},"reference":[{"key":"811_CR1","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1056\/NEJMra1505557","volume":"376","author":"CT Ritchlin","year":"2017","unstructured":"Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2017;376:957\u201370.","journal-title":"N Engl J Med"},{"key":"811_CR2","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.jaad.2013.07.023","volume":"69","author":"PJ Mease","year":"2013","unstructured":"Mease PJ, Gladman DD, Papp KA, et al. Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European\/North American dermatology clinics. J Am Acad Dermatol. 2013;69:729\u201335.","journal-title":"J Am Acad Dermatol"},{"key":"811_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2021.101692","volume":"35","author":"P Karmacharya","year":"2021","unstructured":"Karmacharya P, Chakradhar R, Ogdie A. The epidemiology of psoriatic arthritis: a literature review. Best Pract Res Clin Rheumatol. 2021;35:101692.","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"811_CR4","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1002\/acr.22404","volume":"66","author":"P Helliwell","year":"2014","unstructured":"Helliwell P, Coates L, Chandran V, et al. Qualifying unmet needs and improving standards of care in psoriatic arthritis. Arthritis Care Res. 2014;66:1759\u201366.","journal-title":"Arthritis Care Res"},{"key":"811_CR5","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1136\/ard-2024-225531","volume":"83","author":"L Gossec","year":"2024","unstructured":"Gossec L, Kerschbaumer A, Ferreira RJO, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update. Ann Rheum Dis. 2024;83:706\u201319.","journal-title":"Ann Rheum Dis"},{"key":"811_CR6","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1002\/acr.23789","volume":"71","author":"JA Singh","year":"2019","unstructured":"Singh JA, Guyatt G, Ogdie A, et al. Special article: 2018 American College of Rheumatology\/National Psoriasis Foundation Guideline for the treatment of psoriatic arthritis. Arthritis Care Res (Hoboken). 2019;71:2\u201329.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"811_CR7","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","volume":"18","author":"LC Coates","year":"2022","unstructured":"Coates LC, Soriano ER, Corp N, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol. 2022;18:465\u201379.","journal-title":"Nat Rev Rheumatol"},{"key":"811_CR8","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1002\/art.40851","volume":"71","author":"PJ Mease","year":"2019","unstructured":"Mease PJ, Gladman DD, Collier DH, et al. Etanercept and methotrexate as monotherapy or in combination for psoriatic arthritis: primary results from a randomized, controlled phase\u00a0III trial. Arthritis Rheumatol. 2019;71:1112\u201324.","journal-title":"Arthritis Rheumatol"},{"key":"811_CR9","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1136\/annrheumdis-2019-216500","volume":"79","author":"E Vieira-Sousa","year":"2020","unstructured":"Vieira-Sousa E, Alves P, Rodrigues AM, et al. GO-DACT: a phase\u00a03b randomised, double-blind, placebo-controlled trial of GOlimumab plus methotrexate (MTX) versus placebo plus MTX in improving DACTylitis in MTX-naive patients with psoriatic arthritis. Ann Rheum Dis. 2020;79:490\u20138.","journal-title":"Ann Rheum Dis"},{"key":"811_CR10","unstructured":"U.S. Food and Drug Administration. Xeljanz\u00ae (tofacitinib): highlights of prescribing information. 2024. https:\/\/labeling.pfizer.com\/showlabeling.aspx?id=959. Accessed Jan 23, 2025."},{"key":"811_CR11","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1056\/NEJMoa1615975","volume":"377","author":"P Mease","year":"2017","unstructured":"Mease P, Hall S, FitzGerald O, et al. Tofacitinib or adalimumab versus placebo for psoriatic arthritis. N Engl J Med. 2017;377:1537\u201350.","journal-title":"N Engl J Med"},{"key":"811_CR12","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1056\/NEJMoa1615977","volume":"377","author":"D Gladman","year":"2017","unstructured":"Gladman D, Rigby W, Azevedo VF, et al. Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors. N Engl J Med. 2017;377:1525\u201336.","journal-title":"N Engl J Med"},{"key":"811_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002559","volume":"9","author":"X Leng","year":"2023","unstructured":"Leng X, Lin W, Liu S, et al. Efficacy and safety of tofacitinib in Chinese patients with active psoriatic arthritis: a phase\u00a03, randomised, double-blind, placebo-controlled study. RMD Open. 2023;9:e002559.","journal-title":"RMD Open"},{"key":"811_CR14","doi-asserted-by":"publisher","first-page":"e270","DOI":"10.1016\/S2665-9913(21)00010-2","volume":"3","author":"P Nash","year":"2021","unstructured":"Nash P, Coates LC, Fleishaker D, et al. Safety and efficacy of tofacitinib up to 48\u00a0months in patients with active psoriatic arthritis: final analysis of the OPAL balance long-term extension study. Lancet Rheumatol. 2021;3:e270\u201383.","journal-title":"Lancet Rheumatol"},{"key":"811_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2021-001595","volume":"7","author":"GR Burmester","year":"2021","unstructured":"Burmester GR, Nash P, Sands BE, et al. Adverse events of special interest in clinical trials of rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and psoriasis with 37 066 patient-years of tofacitinib exposure. RMD Open. 2021;7:e001595.","journal-title":"RMD Open"},{"key":"811_CR16","doi-asserted-by":"publisher","first-page":"e28","DOI":"10.1016\/S2665-9913(20)30339-8","volume":"3","author":"P Nash","year":"2021","unstructured":"Nash P, Mease PJ, Fleishaker D, et al. Tofacitinib as monotherapy following methotrexate withdrawal in patients with psoriatic arthritis previously treated with open-label tofacitinib plus methotrexate: a randomised, placebo-controlled substudy of OPAL balance. Lancet Rheumatol. 2021;3:e28\u201339.","journal-title":"Lancet Rheumatol"},{"key":"811_CR17","doi-asserted-by":"publisher","first-page":"e14","DOI":"10.1016\/S2665-9913(22)00329-0","volume":"5","author":"M Koehm","year":"2023","unstructured":"Koehm M, Rossmanith T, Foldenauer AC, et al. Methotrexate plus ustekinumab versus ustekinumab monotherapy in patients with active psoriatic arthritis (MUST): a randomised, multicentre, placebo-controlled, phase\u00a03b, non-inferiority trial. Lancet Rheumatol. 2023;5:e14\u201323.","journal-title":"Lancet Rheumatol"},{"key":"811_CR18","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.3899\/jrheum.151290","volume":"43","author":"B Combe","year":"2016","unstructured":"Combe B, Behrens F, McHugh N, et al. Comparison of etanercept monotherapy and combination therapy with methotrexate in psoriatic arthritis: results from 2 clinical trials. J Rheumatol. 2016;43:1063\u20137.","journal-title":"J Rheumatol"},{"key":"811_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001484","volume":"7","author":"V Strand","year":"2021","unstructured":"Strand V, Mease PJ, Maksabedian Hernandez EJ, et al. Patient-reported outcomes data in patients with psoriatic arthritis from a randomised trial of etanercept and methotrexate as monotherapy or in combination. RMD Open. 2021;7:e001484.","journal-title":"RMD Open"},{"key":"811_CR20","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s40744-023-00631-4","volume":"11","author":"PJ Mease","year":"2024","unstructured":"Mease PJ, Young P, Fallon L, et al. Effectiveness of tofacitinib in patients initiating therapy for psoriatic arthritis: results from the CorEvitas Psoriatic Arthritis\/Spondyloarthritis Registry. Rheumatol Ther. 2024;11:313\u201329.","journal-title":"Rheumatol Ther"},{"key":"811_CR21","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1080\/1744666X.2023.2249237","volume":"19","author":"K Tokareva","year":"2023","unstructured":"Tokareva K, Reid P, Yang V, et al. JAK inhibitors and black box warnings: what is the future for JAK inhibitors? Expert Rev Clin Immunol. 2023;19:1385\u201397.","journal-title":"Expert Rev Clin Immunol"},{"key":"811_CR22","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1515\/sjpain-2019-0054","volume":"20","author":"F Wolfe","year":"2019","unstructured":"Wolfe F, Butler SH, Fitzcharles M, et al. Revised chronic widespread pain criteria: development from and integration with fibromyalgia criteria. Scand J Pain. 2019;20:77\u201386.","journal-title":"Scand J Pain"},{"key":"811_CR23","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2018-000880","volume":"5","author":"PJ Mease","year":"2019","unstructured":"Mease PJ, Karki C, Liu M, et al. Discontinuation and switching patterns of tumour necrosis factor inhibitors (TNFis) in TNFi-naive and TNFi-experienced patients with psoriatic arthritis: an observational study from the US-based Corrona registry. RMD Open. 2019;5:e000880.","journal-title":"RMD Open"},{"key":"811_CR24","unstructured":"Ogdie A, O\u2019Brien J, Malley W, et al. Effectiveness by disease severity in patients with psoriatic arthritis treated with apremilast in the CorEvitas psoriatic arthritis\/spondyloarthritis (PsA\/SpA) Registry [abstract]. Arthritis Rheumatol. 2022;74(Suppl 9)."},{"key":"811_CR25","doi-asserted-by":"publisher","first-page":"3850","DOI":"10.1007\/s12325-024-02904-y","volume":"41","author":"PJ Mease","year":"2024","unstructured":"Mease PJ, Papademetriou E, Potluri R, Agarwal E, Cappelleri JC, Ling YL. Adherence, persistence, healthcare resource use, and costs in tofacitinib-treated patients with psoriatic arthritis: data from two United States claims databases. Adv Ther. 2024;41:3850\u201367.","journal-title":"Adv Ther"},{"key":"811_CR26","doi-asserted-by":"publisher","first-page":"4569","DOI":"10.1007\/s10067-021-05799-0","volume":"40","author":"M Lorenzin","year":"2021","unstructured":"Lorenzin M, Ortolan A, Cozzi G, et al. Predictive factors for switching in patients with psoriatic arthritis undergoing anti-TNF\u03b1, anti-IL12\/23, or anti-IL17 drugs: a 15-year monocentric real-life study. Clin Rheumatol. 2021;40:4569\u201380.","journal-title":"Clin Rheumatol"},{"key":"811_CR27","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s40268-017-0215-7","volume":"17","author":"L Costa","year":"2017","unstructured":"Costa L, Perricone C, Chimenti MS, et al. Switching between biological treatments in psoriatic arthritis: a review of the evidence. Drugs RD. 2017;17:509\u201322.","journal-title":"Drugs RD"},{"key":"811_CR28","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14926","volume":"34","author":"Y Xie","year":"2021","unstructured":"Xie Y, Liu Y, Liu Y. Are biologics combined with methotrexate better than biologics monotherapy in psoriasis and psoriatic arthritis: a meta-analysis of randomized controlled trials. Dermatol Ther. 2021;34:e14926.","journal-title":"Dermatol Ther"},{"key":"811_CR29","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003423","volume":"10","author":"PJ Mease","year":"2024","unstructured":"Mease PJ, Reddy S, Ross S, et al. Evaluating the efficacy of biologics with and without methotrexate in the treatment of psoriatic arthritis: a network meta-analysis. RMD Open. 2024;10:e003423.","journal-title":"RMD Open"},{"key":"811_CR30","doi-asserted-by":"publisher","first-page":"48","DOI":"10.3899\/jrheum.190815","volume":"48","author":"ML Thomas","year":"2021","unstructured":"Thomas ML, Shaddick G, Charlton R, et al. Tumor necrosis factor inhibitor monotherapy versus combination therapy for the treatment of psoriatic arthritis: combined analysis of European biologics databases. J Rheumatol. 2021;48:48\u201357.","journal-title":"J Rheumatol"},{"key":"811_CR31","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2015-000181","volume":"1","author":"PJ Mease","year":"2015","unstructured":"Mease PJ, Collier DH, Saunders KC, Li G, Kremer JM, Greenberg JD. Comparative effectiveness of biologic monotherapy versus combination therapy for patients with psoriatic arthritis: results from the Corrona registry. RMD Open. 2015;1:e000181.","journal-title":"RMD Open"},{"key":"811_CR32","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1002\/acr2.11657","volume":"6","author":"PJ Mease","year":"2024","unstructured":"Mease PJ, Ogdie A, Tesser J, et al. Improvements in patient-reported outcomes through six months of guselkumab treatment in patients with active psoriatic arthritis: real-world data from the CorEvitas psoriatic arthritis\/spondyloarthritis registry. ACR Open Rheumatol. 2024;6:304\u201311.","journal-title":"ACR Open Rheumatol"},{"key":"811_CR33","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s10067-021-05893-3","volume":"41","author":"O Karadag","year":"2022","unstructured":"Karadag O, Dalkilic E, Ayan G, et al. Real-world data on change in work productivity, activity impairment, and quality of life in patients with psoriatic arthritis under anti-TNF therapy: a postmarketing, noninterventional, observational study. Clin Rheumatol. 2022;41:85\u201394.","journal-title":"Clin Rheumatol"},{"key":"811_CR34","doi-asserted-by":"crossref","unstructured":"Dejaco C, Mueller T, Zamani O, et al. A prospective study to evaluate the impact of golimumab therapy on work productivity and activity, and quality of life in patients with rheumatoid arthritis, psoriasis arthritis and axial spondyloarthritis in a real life setting in AUSTRIA. The GO-ACTIVE study. Front Med (Lausanne). 2022;2:881943.","DOI":"10.3389\/fmed.2022.881943"},{"key":"811_CR35","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1007\/s12325-018-0866-y","volume":"36","author":"H Nakagawa","year":"2019","unstructured":"Nakagawa H, Tanaka Y, Sano S, et al. Real-world postmarketing study of the impact of adalimumab treatment on work productivity and activity impairment in patients with psoriatic arthritis. Adv Ther. 2019;36:691\u2013707.","journal-title":"Adv Ther"},{"key":"811_CR36","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s13075-023-03058-y","volume":"25","author":"L Gossec","year":"2023","unstructured":"Gossec L, Siebert S, Bergmans P, et al. Improvement in patient-reported outcomes and work productivity following 3-year ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: results from the PsABio real-world study. Arthritis Res Ther. 2023;25:109.","journal-title":"Arthritis Res Ther"},{"key":"811_CR37","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.1080\/09546634.2021.1950600","volume":"33","author":"C Xu","year":"2022","unstructured":"Xu C, Teeple A, Wu B, Fitzgerald T, Feldman SR. Treatment adherence and persistence of seven commonly prescribed biologics for moderate to severe psoriasis and psoriatic arthritis in a U.S. commercially insured population. J Dermatolog Treat. 2022;33:2270\u20137.","journal-title":"J Dermatolog Treat"},{"key":"811_CR38","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1093\/rheumatology\/keu358","volume":"54","author":"J Bluett","year":"2015","unstructured":"Bluett J, Morgan C, Thurston L, et al. Impact of inadequate adherence on response to subcutaneously administered anti-tumour necrosis factor drugs: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort. Rheumatology (Oxford). 2015;54:494\u20139.","journal-title":"Rheumatology (Oxford)"},{"key":"811_CR39","doi-asserted-by":"publisher","first-page":"949","DOI":"10.2147\/PPA.S242336","volume":"14","author":"D Aletaha","year":"2020","unstructured":"Aletaha D, Husni ME, Merola JF, et al. Treatment mode preferences in psoriatic arthritis: a qualitative multi-country study. Patient Prefer Adherence. 2020;14:949\u201361.","journal-title":"Patient Prefer Adherence"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-025-00811-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-025-00811-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-025-00811-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T14:52:34Z","timestamp":1768834354000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-025-00811-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,4]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["811"],"URL":"https:\/\/doi.org\/10.1007\/s40744-025-00811-4","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,4]]},"assertion":[{"value":"4 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Alexis Ogdie has received consultancy fees for AbbVie, Amgen, Bristol Myers Squibb, Celgene, CorEvitas, LLC, Gilead, GSK, Janssen, Lilly, Novartis, Pfizer Inc, Takeda, TREG, and UCB, and research grants for AbbVie, Amgen, Bristol Myers Squibb, Forward\/National Databank for Rheumatic Diseases, Janssen, NIH\/NIAMS, Novartis, Pfizer Inc, and Rheumatology Research Foundation. Nicole Middaugh is an employee of CorEvitas, LLC (CorEvitas has been supported through contracted subscriptions in the past 2\u00a0years by AbbVie, Amgen, Arena, Boehringer Ingelheim, Bristol Myers Squibb, Chugai, Lilly, Genentech, GSK, Janssen, LEO Pharma, Novartis, Ortho Dermatologics, Pfizer Inc, Sun Pharmaceutical Industries Ltd, and UCB). Taylor Blachley is an employee of CorEvitas, LLC (CorEvitas has been supported through contracted subscriptions in the past 2\u00a0years by AbbVie, Amgen, Arena, Boehringer Ingelheim, Bristol Myers Squibb, Chugai, Lilly, Genentech, GSK, Janssen, LEO Pharma, Novartis, Ortho Dermatologics, Pfizer Inc, Sun Pharmaceutical Industries Ltd, and UCB). Tran Bourgeois was an employee of CorEvitas, LLC, at the time of the study (CorEvitas has been supported through contracted subscriptions in the past 2\u00a0years by AbbVie, Amgen, Arena, Boehringer Ingelheim, Bristol Myers Squibb, Chugai, Lilly, Genentech, GSK, Janssen, LEO Pharma, Novartis, Ortho Dermatologics, Pfizer Inc, Sun Pharmaceutical Industries Ltd, and UCB), and is now an employee of the Children\u2019s Hospital of Philadelphia, PA, USA. You-Li Ling is an employee and stockholder of Pfizer Inc. Rajiv Mundayat, Princeton, NJ, USA, is a stockholder of Pfizer Inc and was an employee of Pfizer Inc at the time of the study. Lara Fallon is an employee and stockholder of Pfizer Inc. Karim R. Masri is a stockholder of Pfizer Inc and was an employee of Pfizer Inc at the time of the study, and is now an employee of Candid Therapeutics. Philip J. Mease has been advisor or review panel member for Genascence\u2013Safety Monitoring Board, has received consultancy fees from AbbVie, Acelyrin, Aclaris, Alumis, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Lilly, Inmagene, Janssen, MoonLake, Novartis, Pfizer Inc, Takeda, UCB, and Ventyx, has been an officer and board member for Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), OMERACT, and SPARTAN, and has received grant\/research support from Amgen, Acelyrin, Bristol Myers Squibb, Lilly, Janssen, Novartis, Pfizer Inc, and UCB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was performed in accordance with Good Pharmacoepidemiology Practice. Sponsor approval and continuing review were obtained through a central Institutional Review Board (IRB), WCG IRB (no. 120160070). All registry participants provided informed consent and authorization prior to participation. CorEvitas PsA\/SpA Registry data used in this analysis were provided in an anonymized structured format and did not contain any patient personal information. This study was performed in accordance with the Helsinki Declaration of 1964 and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}